SanBio Co Ltd (TSE:4592)
円 1150 375 (48.39%) Market Cap: 78.92 Bil Enterprise Value: 75.56 Bil PE Ratio: 0 PB Ratio: 32.88 GF Score: 35/100

Q2 2022 SanBio Co Ltd Earnings Call Transcript

Sep 16, 2021 / NTS GMT
Release Date Price: 円1251 (-3.99%)
Keita Mori
SanBio Company Limited - Co-Founder, President, Executive Officer & Representative Director

Good afternoon. This is Keita Mori from SanBio. Thank you for all the investors and other people to attending this meeting today. It's a pleasure for us to present to this many audiences today.

We met the 20 years anniversary this year, earlier this year. And we continue to strive towards developing pioneering regenerative medicine and developing the first brain regenerative medicine, which has been wanted for more than, I guess, 100 years or so.

So we have 3 contents today starting from the financial results. First, I'd like to go over the income statement. As you can see, the R&D, research and development expenses increased due to higher manufacturing-related expenses in preparation for approval filing of SB623 for TBI. As you can see, our R&D expense was about $22 million in the last 6 months, and that there is some increase, again, from the additional expenses in the manufacturing.

Next, I'd like to go to the balance sheet. As we are continuing to be still in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot